636 related articles for article (PubMed ID: 24074240)
1. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
[TBL] [Abstract][Full Text] [Related]
2. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
3. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
Katzman MA; Sternat T
CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
[TBL] [Abstract][Full Text] [Related]
4. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
[TBL] [Abstract][Full Text] [Related]
8. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
[TBL] [Abstract][Full Text] [Related]
9. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.
van der Schans J; Kotsopoulos N; Hoekstra PJ; Hak E; Postma MJ
PLoS One; 2015; 10(5):e0127237. PubMed ID: 26024479
[TBL] [Abstract][Full Text] [Related]
11. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
[TBL] [Abstract][Full Text] [Related]
12. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
13. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.
Döpfner M; Breuer D; Walter D; Rothenberger A
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S277-88. PubMed ID: 21901414
[TBL] [Abstract][Full Text] [Related]
14. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Gormez V; Avery B; Mann H
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
Maldonado R
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1001-14. PubMed ID: 23611637
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Wigal SB; Gupta S; Heverin E; Starr HL
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
[TBL] [Abstract][Full Text] [Related]
18. The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.
Zelnik N; Terkel-Dawer R
Atten Defic Hyperact Disord; 2015 Dec; 7(4):313-8. PubMed ID: 25838111
[TBL] [Abstract][Full Text] [Related]
19. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
Maia CR; Matte BC; Ludwig HT; Rohde LA
Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
[TBL] [Abstract][Full Text] [Related]
20. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
